Medicina molecular Non multum sed multa et nos mutamur La sublevación cancerosa

Contenido principal del artículo

Mario Castañeda Morales

Resumen

La célula cancerosa es una entidad cuya existencia dentro de nuestro organismo se antoja, a primera vista, aberrante. Es decir, no debería sobrevivir en el organismo. ¿Acaso no contamos con un sistema inmune de reconocimiento y selección negativa? ¿Qué sucede con la red inmune, con los linfocitos citotóxicos T (CTL) y los asesinos naturales (NK) que rastrean y matan esas células? ¿Por qué no responden? Y si lo hacen, ¿por qué tan ineficientemente? Éstas son preguntas básicas en biomedicina.

Detalles del artículo

Cómo citar
1.
Medicina molecular Non multum sed multa et nos mutamur La sublevación cancerosa. RSM [Internet]. 2024 Apr. 29 [cited 2025 Feb. 17];51(2). Available from: https://revistasanidadmilitar.org/index.php/rsm/article/view/1105
Sección
Artículos de investigación

Cómo citar

1.
Medicina molecular Non multum sed multa et nos mutamur La sublevación cancerosa. RSM [Internet]. 2024 Apr. 29 [cited 2025 Feb. 17];51(2). Available from: https://revistasanidadmilitar.org/index.php/rsm/article/view/1105

Referencias

Barnd DL, Lan MS, Metzgar RS y Finn OJ. Specifíc major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989; 86: 7159-63.

Jerome KR. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recogníze an epitope present on a protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991; 51: 2908-16.

Disís ML. Existent T-cell and antibody immunity to HER-2/neu proteín in patients with breast cancer. Cancer Res 1994; 54: 16-20.

van de Bruggen P. A gene encoding an antigen recognized by cytolytic T lymphocytes on human melanoma. Science 1994; 54: 1643-7.

Ioannides C y Whiteside T. T cell recognition of human tumors: Implications for molecular immunotherapy of cáncer. Clin Immunol Immunopathol 1993,66: 91-106.

Belldegrun A, Kasid A, Uppenkamp M, Topalian SL y Rosenberg SA. Human tumor infiltrating lymphocytes: Analysis of lymphokine mRNA expression and relevance to cáncer immunotherapy. J Immunol 1989; 42: 4520-6.

Huang AYC. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264: 961-5.

Watson G y López DM. Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses. J Immunol 1995; 155: 3124-34.

Toriyama K, Wen DR, Paul E, y Cochea AJ. Variation in the distribution frequency and phenotype of Langerhans cells during the evolution of malignant melanoma of the skin. J Invest Dennat 1993; 100: 269S-73.

Gravilovich DI, Nadaf S, Corack J, Berzofsky JA y Carbone DP. Dendritic cells in anti-tumor immune response II Denditric cells grown from bone marrow precursors, but not mature DC, from tumor-bearing rnice are effective antigen carriers in the therapy of stablished tumors, Cell Immunol 1996; 170: 111-20.

Bossi P. Angiogenesis in colorectal turnors microvessel quantítation in adenomas and carcinomas with clinicopathologícal correlations. Cancer Res 1995; 55: 5049-53.

Katoh O, Tauchi H, Kawaishi K, Kirnura A y Satow Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in. hernatopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 1995; 55: 5687-92.

Corallini A. Systemic expression of HIV-1 tat gene in transgenic mice induces endothelial proliferation and tumors of different histotypes. Cancer Res 1993; 53: 5569-75.

Hayes DF, Silbersteín DS, Rodríguez S y Kufe DW. DF-3 antigen, a human epithelial cell mucin, inhibits adhesion of eosinophils to antibo- dy-coated targets. J Immunol 1990; 145: 962-70.

Castañeda M. Muerte celular. En: Envejecimiento: La última aventura. Fondo de Cultura Económica. México, D.F. 1994: 76-84.

Hughes DE. Bisphosphonates promete apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10: 1478-87.

Yang NN. ldentification of an estrogen response element activated by metabolites and 17 beta-estradiol and raloxifene. Science 1996; 273: 1222-4.

Gips SJ, Alvarez RJ, Millike EE, Dang CV, Goldschmidt-Clermont PJ. 17-beta estradiol inhibits apoptosis of cultured endothelial cells. J Am Coll Cardiol 1996; 27: 384A.

Nagata S y Suda T. Fas and Fas ligand: lpr and gld mutations. lmmunol Today 1995; 16: 39-43.

Hahne M. Melanoma cell expression of fas (Apo- I/CD-95) ligand: implications for tumor immune escape. Science 1996; 274: 1363-1366.

O'Connell J, O' Sullivan GC, Collins JK y Shanahan F. The fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-82.

Galle PR. Involvement of the CD95 (APO-1/Fas) receptor and ligand Iiver damage. J Exp Med 1995; 182: 1223-30.

Griffith T, Brunner T. Fletcher S, Green D y Ferguson T. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-92.

Lan H, Yu M, Fontana A y Stoeckert C. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 273: 109-12.